Trial Profile
Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms TRAIN
- 01 Mar 2017 Results reporting the efficacy and toxicity of weekly paclitaxel-trastuzumab-carboplatin as neo-adjuvant treatment, published in the European Journal of Cancer.
- 10 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2008 New trial record.